Abatacept for the treatment of rheumatoid arthritis.

Abstract:

INTRODUCTION:Rheumatoid arthritis (RA) is a complex disease in which different mechanisms are involved. Studies suggest a key role for aberrant pathways of T-cell activation in the initiation and perpetuation of disease. Abatacept is a fusion protein composed of the Fc region of the immunoglobulin G1 (IgG1) fused to the extracellular domain of cytotoxic T lymphocyte-associated antigen (CTLA4). It has the ability to modulate T-cell activation by interfering with co-stimulation of these cells, a necessary step to become activated. This suggests that abatacept may play a role in the progression and/or even the initiation of RA. Areas covered: a review of the different studies carried out during clinical development of abatacept was performed. Both formulations, intravenous (IV) and subcutaneous (SC), showed a similar and consistent efficacy and safety profile. Abatacept was effective both in RA patients not responding to methotrexate (MTX) and to tumor necrosis factor (TNF) inhibitors. Expert commentary: abatacept, with its unique mechanism of action, proved to be a useful therapeutic alternative in RA, also having an acceptable safety profile. Evidence points out that abatacept may be able to alter the RA disease course. Ongoing studies will clarify this issue.

authors

Pombo-Suarez M,Gomez-Reino JJ

doi

10.1080/1744666X.2019.1579642

subject

Has Abstract

pub_date

2019-04-01 00:00:00

pages

319-326

issue

4

eissn

1744-666X

issn

1744-8409

journal_volume

15

pub_type

杂志文章,评审
  • Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus.

    abstract:INTRODUCTION:Despite the emergence of newer immunomodulating agents for systemic lupus erythematosus (SLE), a substantial proportion of patients still do not respond optimally. While the mechanisms for the differential responses to drug therapy are unclear, variation in drug exposure with the same dosing protocol relat...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1212659

    authors: Mok CC

    更新日期:2017-01-01 00:00:00

  • Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatment.

    abstract::Methotrexate (MTX) is the key treatment in juvenile idiopathic arthritis (JIA). Nevertheless, MTX is not always sufficiently efficacious and can lead to adverse effects, which compromises complete disease control. In such cases, combination therapies with biologicals are given, even at MTX start, before knowing the pa...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2014.916617

    authors: Ćalasan MB,Wulffraat NM

    更新日期:2014-07-01 00:00:00

  • Dupilumab for the treatment of adolescents with atopic dermatitis.

    abstract:INTRODUCTION:Dupilumab is a treatment option newly licensed for adolescents with moderate to severe atopic dermatitis (AD). It reduces type 2 inflammation by blocking the shared receptor subunit for IL-4/-13. Dupilumab affects three disease mechanisms in atopic dermatitis: the skin barrier, the Th2-cell differentiation...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1080/1744666X.2020.1801420

    authors: Senner S,Seegräber M,Frey S,Kendziora B,Eicher L,Wollenberg A

    更新日期:2020-07-01 00:00:00

  • Brodalumab for the treatment of psoriasis.

    abstract:INTRODUCTION:Psoriasis is a complex disease in which the alteration of the IL-23/Th17 axis appears to be crucial for its pathogenic mechanisms, and anti-IL17 agents are rapidly becoming important therapeutic tools. Brodalumab, a fully human Chinese hamster ovary cell-derived immunoglobulin G2 (IgG2) anti-IL-17RA monocl...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1246957

    authors: Galluzzo M,D'adamio S,Bianchi L,Talamonti M

    更新日期:2016-12-01 00:00:00

  • The multifaceted aspects of refractory lupus nephritis.

    abstract::The term refractory lupus nephritis is generally used to indicate cases that do not respond to traditional treatment. However, the clinical presentation of lupus nephritis is variable and the time to response depends on the typology of the underlying renal syndrome. The criteria and the time for response are different...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2015.990883

    authors: Moroni G,Ponticelli C

    更新日期:2015-02-01 00:00:00

  • CD40 ligand deficiency: treatment strategies and novel therapeutic perspectives.

    abstract:INTRODUCTION:CD40 ligand (CD40L) deficiency or X-linked Hyper-IgM syndrome is a severe primary immunodeficiency caused by mutations in the CD40L gene. Despite currently available treatments, CD40L-deficient patients remain susceptible to life-threatening infections and have poor long term survival. Areas covered: Here,...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2019.1573674

    authors: França TT,Barreiros LA,Al-Ramadi BK,Ochs HD,Cabral-Marques O,Condino-Neto A

    更新日期:2019-05-01 00:00:00

  • STAT1 and STAT3 mutations: important lessons for clinical immunologists.

    abstract:INTRODUCTION:The transcription factors signal transducer and activator of transcription (STAT) 1 and STAT3 fulfill fundamental functions in nonimmune and immune cells. The description and follow-up of patients with germline mutations that result in either loss-of-function or gain-of-function have contributed to our und...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2018.1531704

    authors: Olbrich P,Freeman AF

    更新日期:2018-12-01 00:00:00

  • Thymic stromal lymphopoietin and the pathophysiology of atopic disease.

    abstract::Thymic stromal lymphopoietin (TSLP) is an IL-7-related cytokine expressed predominantly by barrier epithelial cells. TSLP is a potent activator of several cell types, including myeloid-derived dendritic cells, monocytes/macrophages and mast cells. Recent studies have revealed an important role for TSLP in the initiati...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/eci.09.45

    authors: Miazgowicz MM,Headley MB,Larson RP,Ziegler SF

    更新日期:2009-09-01 00:00:00

  • Prediction of treatment outcome and relapse in inflammatory bowel disease.

    abstract:INTRODUCTION:Prediction of treatment outcome and clinical relapse in patients with inflammatory bowel disease (IBD), either ulcerative colitis (UC) or Crohn's disease (CD), is particularly important because therapeutics for IBD are not always effective and patients in remission could frequently relapse. Because undergo...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2019.1593140

    authors: Kato J,Yoshida T,Hiraoka S

    更新日期:2019-06-01 00:00:00

  • Cardiovascular comorbidities in antiphospholipid syndrome.

    abstract::Antiphospholipid syndrome is an autoimmune disease characterized by venous and/or arterial thrombosis and/or recurrent fetal loss and the presence of antiphospholid antibodies. Among the causes of death of antiphospholipid syndrome there are the myocardial infarction and stroke. Comorbidities could worsen the evolutio...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2013.837261

    authors: Muniz Caldas CA,Freire de Carvalho J

    更新日期:2013-10-01 00:00:00

  • Regulatory T cells: the future of autoimmune disease treatment.

    abstract::Introduction: CD4 + T regulatory cells (Tregs) have been described as the most potent immunosuppressive cells in the human body. They have been found to control autoimmunity, and clinical attempts have been made to apply them to treat autoimmune diseases. Some specific pathways utilized by Tregs in the regulation of i...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2019.1620602

    authors: Ryba-Stanisławowska M,Sakowska J,Zieliński M,Ławrynowicz U,Trzonkowski P

    更新日期:2019-07-01 00:00:00

  • Dendritic cell-based therapy in Type 1 diabetes mellitus.

    abstract::Dendritic cell (DC) immunotherapy is a clinical reality. Despite two decades of considerable data demonstrating the feasibility of using DCs to prolong transplant allograft survival and to prevent autoimmunity, only now are these cells entering clinical trials in humans. Type 1 diabetes is the first autoimmune disorde...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/eci.09.8

    authors: Phillips B,Giannoukakis N,Trucco M

    更新日期:2009-05-01 00:00:00

  • An overview of T follicular cells in transplantation: spotlight on their clinical significance.

    abstract::Introduction: For late stage organ failure patients, transplantation is the best option to increase life expectancy with a superior quality of life. Unfortunately, after transplantation many patients are at risk of cellular and antibody-mediated rejection (ABMR). The latter is initiated by donor specific antibodies (D...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2020.1693262

    authors: Niu Q,Kraaijeveld R,Li Y,Mendoza Rojas A,Shi Y,Wang L,Van Besouw NM,Baan CC

    更新日期:2019-12-01 00:00:00

  • Treatment of pemphigus vulgaris: part 1 - current therapies.

    abstract::Introduction: While biologic agents that can be used for treating pemphigus vulgaris (PV) are increasing, themajority of the world's PV patients can afford only corticosteroids (CS) and some immunosuppressive agents (ISA). Areas covered: The spectrum of side effects encountered when PV patients receive high-dose, long...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2020.1672535

    authors: Yanovsky RL,McLeod M,Ahmed AR

    更新日期:2019-10-01 00:00:00

  • Delayed diagnosis in X-linked agammaglobulinemia and its relationship to the occurrence of mutations in BTK non-kinase domains.

    abstract:BACKGROUND:X-linked agammaglobulinemia (XLA) is characterized by the absence of immunoglobulin and B cells. Patients suffer from recurrent bacterial infections from early childhood, and require lifelong immunoglobulin replacement therapy. Mutations in BTK (Bruton's Tyrosine Kinase) are associated with this phenotype. S...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1080/1744666X.2018.1413349

    authors: Carrillo-Tapia E,García-García E,Herrera-González NE,Yamazaki-Nakashimada MA,Staines-Boone AT,Segura-Mendez NH,Scheffler-Mendoza SC,O Farrill-Romanillos P,Gonzalez-Serrano ME,Rodriguez-Alba JC,Santos-Argumedo L,Berron-Ruiz L,Sanc

    更新日期:2018-01-01 00:00:00

  • Epithelial physical barrier defects in chronic rhinosinusitis.

    abstract:INTRODUCTION:Chronic rhinosinusitis (CRS) is a common upper airway disease with a prevalence of greater than 10% of the general population. Although the pathogenesis of CRS remains poorly understood, there is growing evidence indicating that epithelial physical barrier defects play an important role in CRS pathogenesis...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2019.1601556

    authors: Jiao J,Wang C,Zhang L

    更新日期:2019-06-01 00:00:00

  • Tuberculosis in the course of sarcoidosis treatment: is genotyping necessary for personalized therapy?

    abstract::Pathological similarities between sarcoidosis (SA) and tuberculosis (TB) suggest that mycobacterial antigen(s), in genetically different predisposed hosts, may be a cause of SA. The authors' work and other published comparative analyses of HLA and non-HLA alleles in patients with SA or TB from different ethnic groups ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.13.8

    authors: Dubaniewicz A,Zimmermann A,Dudziak M,Typiak M,Skotarczak M

    更新日期:2013-04-01 00:00:00

  • Barriers to successful transplantation of the sensitized patient.

    abstract::Antibody present in the transplant recipient that yields a positive crossmatch with donor cells has long been considered a contraindication and an absolute barrier to transplantation. However, improved methods of antibody detection and characterization have shown that some reactivity with donor cells may be inconseque...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.10.14

    authors: Zachary AA,Leffell MS

    更新日期:2010-05-01 00:00:00

  • Combining desloratadine and pseudoephedrine in the treatment of seasonal allergic rhinitis.

    abstract::Nonsedating antihistamines are a first-line therapy in the management of allergic rhinitis. They relieve the majority of the histamine-mediated symptoms of the condition, including rhinorrhea, sneezing, and pruritus. The nonsedating antihistamine desloratadine is effective in alleviating the symptoms of both seasonal ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.2.4.519

    authors: Schenkel EJ

    更新日期:2006-07-01 00:00:00

  • New frontiers in reproductive immunology research: bringing bedside problems to the bench.

    abstract::The 31st Annual Meeting of the American Society for Reproductive Immunology provided an excellent platform for basic and clinical scientists to brainstorm on current reproductive health issues such as repeated implantation and pregnancy failure, preterm birth, preeclampsia and genital tract infections such as HIV. The...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/eci.11.47

    authors: Joukhadar J,Nevers T,Kalkunte S

    更新日期:2011-09-01 00:00:00

  • Targeting signaling pathways with small molecules to treat autoimmune disorders.

    abstract::Chronic activation of immune responses, mediated by inflammatory mediators and involving different effector cells of the innate and acquired immune system characterizes autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease, psoriasis and septic shock syndrome. MAPKs are crucial intracellular m...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.4.1.93

    authors: Kaminska B,Swiatek-Machado K

    更新日期:2008-01-01 00:00:00

  • Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

    abstract::Rheumatoid arthritis (RA) is a chronic inflammatory systemic disease characterized by symmetric arthritis leading to progressive erosion of cartilage and bone. Psoriatic arthritis and ankylosing spondylitis are also inflammatory arthritides that belong to the spondyloarthritides. Disease-modifying anti-rheumatic drugs...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.10.49

    authors: Voulgari PV

    更新日期:2010-09-01 00:00:00

  • The pathogenesis of the secondary forms of autoimmune inner ear disease (AIED): advancing beyond the audiogram data.

    abstract:INTRODUCTION:Autoimmune Inner Ear Disease (AIED) can be of a primary or secondary type. To date, a clear pathogenesis of the disease is still not available. Focusing on the secondary forms of AIED, the aim of this review is to (i) assess and describe the hearing involvement in patients affected by autoimmune diseases, ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1080/1744666X.2021.1879640

    authors: Corazzi V,Hatzopoulos S,Bianchini C,Skarżyńska MB,Pelucchi S,Skarżyński PH,Ciorba A

    更新日期:2021-01-21 00:00:00

  • Omalizumab for the treatment of chronic urticaria.

    abstract::Urticaria is a common and often debilitating dermatological condition defined by the sudden appearance of wheals, angioedema or both. It is further classified into specific subtypes based on duration and specific triggers. Awareness and understanding of urticaria are important to ensure a correct initial diagnosis and...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2015.993971

    authors: Zuberbier T,Maurer M

    更新日期:2015-02-01 00:00:00

  • Harnessing immunotherapy for pediatric T-cell malignancies.

    abstract::Pediatric T-cell hematologic malignancies are a diverse group of rare cancers. The most common pediatric T-cell malignancies include T-cell acute lymphoblastic leukemia (T-ALL) and anaplastic large cell lymphoma (ALCL). Although the overall survival rates have improved markedly in recent years, children with relapsed ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1080/1744666X.2020.1732819

    authors: Diorio C,Teachey DT

    更新日期:2020-04-01 00:00:00

  • Chronotherapy with modified-release prednisone in patients with rheumatoid arthritis.

    abstract::Glucocorticoids are indispensable for the treatment of systemic inflammatory diseases such as rheumatoid arthritis (RA), though their beneficial effects have to be balanced with potential complications arising from high doses, prolonged use or dose splitting. A glucocorticoid formulation (modified-release prednisone) ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.11.95

    authors: Alten R

    更新日期:2012-02-01 00:00:00

  • Adalimumab for the treatment of psoriatic arthritis.

    abstract::Psoriatic arthritis (PsA) is a chronic inflammatory joint disease occurring in 6-39% of patients with psoriasis. Standard therapy of PsA includes nonsteroidal anti-inflammatory drugs, intra-articular steroids and disease-modifying antirheumatic drugs. Failure of standard therapy is an indication for anti-TNF-alpha the...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/eci.09.50

    authors: Poddubnyy DA,Rudwaleit M

    更新日期:2009-11-01 00:00:00

  • Certolizumab pegol: a new biologic targeting rheumatoid arthritis.

    abstract::The past decade has been an exciting period for clinical research and patient care in rheumatoid arthritis. This is mostly due to targeted biologic agents that have changed the outcome of this disease. Certolizumab pegol (Cimzia(®), UCB Inc., GA, USA), which targets TNF-α with a different mechanism of action than wide...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.10.69

    authors: Patel AM,Moreland LW

    更新日期:2010-11-01 00:00:00

  • Treatment and monitoring of hypersensitivity pneumonitis.

    abstract:INTRODUCTION:Hypersensitivity pneumonitis (HP) is an immunologically induced lung disease that develops after inhalation of certain environmental antigens only in subjects with susceptibility to antigens. Therefore, both environmental and host immunological factors play important roles in the aetiology and pathogenesis...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1182426

    authors: Miyazaki Y,Tsutsui T,Inase N

    更新日期:2016-09-01 00:00:00

  • A focus on the use of subcutaneous C1-inhibitor for treatment of hereditary angioedema.

    abstract:INTRODUCTION:HAE is a very debilitating disease that causes significant distress for patients not only during an acute attack but also constant fear for a subsequent attack. It is important to address long-term prophylactic (LTP) therapy to prevent attacks, decrease morbidity and increase the quality of life. When disc...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1080/1744666X.2020.1750953

    authors: Villavicencio MF,Craig T

    更新日期:2020-05-01 00:00:00